CollPlant Biotechnologies Ltd. logo
CollPlant Biotechnologies Ltd. CLGN
$ 0.56 -0.35%

Annual report 2024
added 02-21-2026

report update icon

CollPlant Biotechnologies Ltd. Financial Statements 2011-2026 | CLGN

Annual Financial Statements CollPlant Biotechnologies Ltd.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

28.2 M 59.7 M 73.9 M 163 M 74.2 M 28.4 M 18.4 M - 4.84 M - - - - -

Shares

11.5 M 11.4 M 11 M 9.97 M 6.89 M 4.99 M 4.38 M - 889 K - - - - -

Historical Prices

2.46 5.24 6.7 16.4 10.8 5.7 4.2 - - - - - - -

Net Income

-16.6 M -7.02 M -16.9 M 237 K -5.77 M -11.2 M -6.25 M -6.01 M -7.25 M -4.78 M -3.34 M -4.73 M -4.6 M -

Revenue

- - - 15.6 M 6.14 M 2.32 M 18 M 480 K 75.9 K - - - - -

Cost of Revenue

1.62 M 1.99 M 400 K 2 M 3 M 1.88 M 1.66 M - - - - - - -

Gross Profit

-1.11 M 8.97 M -101 K 13.6 M 3.14 M 439 K 3.36 M 465 K 75.9 K - - - - -

Operating Income

-17.3 M -7.51 M -17.1 M 65 K -5.6 M -7.63 M -4.24 M - - - - - - -

EBITDA

-16.2 M -6.41 M -16 M 838 K -4.94 M -7.09 M -3.9 M -5.96 M -7.15 M -4.62 M -3.29 M -4.37 M -4.29 M -

Operating Expenses

- - - - 8.73 M 8.07 M 8.48 M 6.44 M 7.24 M - - - - -

General and Administrative Expenses

- - - 5.94 M 4.62 M 3.66 M 12.5 M 2.38 M 2.86 M 1.77 M 945 K 1.01 M 1.28 M -

All numbers in USD currency

Quarterly Income Statement CollPlant Biotechnologies Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - 10.8 M - 10.2 M - 6.96 M - 6.96 M - 5.67 M - 4.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - - - -3.04 M - - - -1.97 M - - - -1.25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - 691 K - - - 823 K - - - 606 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - 429 K - - - 748 K - - - 463 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - 262 K - - - 75 K - - - 143 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - -3.06 M - - - -1.91 M - - - -1.76 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - -3.06 M - - - -1.91 M - - - -1.76 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - - 1.42 M - - - 986 K - - - 820 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements CollPlant Biotechnologies Ltd. CLGN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting CollPlant Biotechnologies Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
AbbVie AbbVie
ABBV
$ 232.08 3.29 % $ 411 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.61 0.56 % $ 1.08 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.12 -1.54 % $ 109 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.66 -0.85 % $ 773 M canadaCanada
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 24.56 -0.32 % $ 4.07 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.56 -3.59 % $ 90.4 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.93 -1.01 % $ 229 M schweizSchweiz
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 2.87 -8.31 % $ 352 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Adagene Adagene
ADAG
$ 2.96 -4.67 % $ 167 M chinaChina
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.1 -0.73 % $ 105 M schweizSchweiz
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 2.53 - $ 16.4 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 15.57 2.57 % $ 3.71 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 16.02 -2.67 % $ 2.43 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 0.46 -4.63 % $ 6.06 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Agenus Agenus
AGEN
$ 3.33 -0.89 % $ 1.19 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 30.23 0.83 % $ 1.75 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.91 -8.59 % $ 43.8 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.31 -0.76 % $ 337 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 0.24 -8.87 % $ 5.73 B britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 5.46 -0.73 % $ 328 M usaUSA
Alector Alector
ALEC
$ 2.43 -5.08 % $ 250 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 7.03 -6.27 % $ 452 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 30.1 -2.05 % $ 4.96 B irlandaIrlanda
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 2.78 1.83 % $ 436 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 332.92 0.51 % $ 43.6 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Altimmune Altimmune
ALT
$ 4.31 -3.36 % $ 306 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 2.11 -10.21 % $ 110 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Amgen Amgen
AMGN
$ 388.16 2.33 % $ 209 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA